Benzinga · Sep 8, 2026
JP Morgan Maintains Overweight on Vera Therapeutics, Raises Price Target to $83
JP Morgan analyst Anupam Rama maintains Vera Therapeutics (NASDAQ:VERA) with a Overweight and raises the price target from $76 to $83.
VE
NASDAQ · VERA
Vera Therapeutics, Inc.
Healthcare · Biotechnology
$33.67
Down-$0.38 (-1.12%)
Updated Sep 16, 2026, 6:28 AM
SID Score
4.8/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 2.94B
- P/E ratio
- -13.44
- Dividend yield
- 0.00%
- 52-week range
- $28.86 – $47.00
- Volume
- 10.49M
- Avg. volume
- 1.59M
Price performance
VERA price history
1M range · 20 trading sessions · Daily adjusted prices
VERA closed at $33.67 after 20 trading sessions, up 4.31% for the selected period.
- Last close
- $33.67
- Period change
- +4.31%
- Period low
- $31.26
- Period high
- $36.82
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $37.14 | $37.14 | $32.73 | $33.67 | 10.49M |
| Sep 14, 2026 | $35.11 | $35.535 | $33.22 | $34.05 | 1.71M |
| Sep 11, 2026 | $33.91 | $35.29 | $33.75 | $35.05 | 3.8M |
| Sep 10, 2026 | $33.49 | $34.29 | $32.88 | $33.60 | 2.03M |
| Sep 9, 2026 | $34.84 | $35.4829 | $33.75 | $33.78 | 939.21K |
| Sep 8, 2026 | $35.80 | $35.995 | $34.885 | $35.28 | 1.44M |
| Sep 4, 2026 | $34.69 | $36.41 | $34.69 | $35.89 | 1.18M |
| Sep 3, 2026 | $35.53 | $35.74 | $34.53 | $34.99 | 929.05K |
| Sep 2, 2026 | $34.44 | $35.73 | $33.8107 | $35.66 | 1.76M |
| Sep 1, 2026 | $33.73 | $34.40 | $33.65 | $34.23 | 4.07M |
| Aug 31, 2026 | $33.64 | $34.38 | $33.18 | $34.08 | 1.54M |
| Aug 28, 2026 | $34.40 | $34.47 | $33.34 | $34.19 | 1.26M |
| Aug 27, 2026 | $36.70 | $36.70 | $34.10 | $34.60 | 2.78M |
| Aug 26, 2026 | $35.10 | $36.96 | $34.6401 | $36.82 | 2.38M |
| Aug 25, 2026 | $34.05 | $35.57 | $34.00 | $35.28 | 2.49M |
| Aug 24, 2026 | $32.25 | $35.0917 | $32.02 | $33.72 | 2.41M |
| Aug 21, 2026 | $31.42 | $32.97 | $31.0331 | $32.275 | 1.29M |
| Aug 20, 2026 | $32.295 | $32.295 | $30.72 | $31.26 | 1.56M |
| Aug 19, 2026 | $32.88 | $33.48 | $31.70 | $32.275 | 1.26M |
| Aug 18, 2026 | $31.31 | $32.3499 | $31.31 | $32.28 | 1.03M |
Latest VERA news
The latest Smart Investors Daily articles mentioning VERA.
Stock researchCompany · Overview
VERA research
Overview
Company profile and research snapshot.
Company profile
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $73.25
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 8, 2026 | JP Morgan | Overweight | — |
| Aug 17, 2026 | Wedbush | Neutral | — |
| Aug 12, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 11, 2026 | Wedbush | Neutral | — |
| Jul 8, 2026 | TD Cowen | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Sep 4, 2026
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on September 1, 2026, the Compensation Committee of the Board of Directors (Compensation Committee) of Vera Therapeutics granted inducement awards consisting of non-qualified stock options to purchase 61,500 shares of Class A common stock and restricted stock units (RSUs) underlying 30,750 shares of Class A common stock to six (6) new employees under the Vera Therapeutics, Inc. 2024
Yahoo · Sep 1, 2026
Vera Therapeutics to Participate at Upcoming Investor Conferences
BRISBANE, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a commercial-stage biotechnology company, today announced that the Company’s management team will present and participate in one-on-one meetings at upcoming investor conferences. Investor Conference Details: Cantor Global Healthcare Conference 2026Format: Fireside Chat and 1x1 investor meetings Webcast: https://sqps.onstreamsecure.com/origin/enliven/players/EnlivenPlayer.html?customerId=22&eventId=395559
SeekingAlpha · Aug 17, 2026
Vera Therapeutics: FDA's eGFR Analysis Supports A Speculative Buy
Vera Therapeutics is upgraded to Buy following TRUTAKNA's FDA approval and encouraging eGFR data. Learn more about VERA stock here.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
